| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.092 | 0.04 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.08 | 0.07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.08 | 0.09 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.047 | 0.3 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.036 | 0.4 |